DDInter923 DDInter604
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Budesonide
Budesonide {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Formestane
Formestane {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Budesonide
Budesonide {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Drospirenone
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Drospirenone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Drospirenone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Formestane (Compound) and Formestane (Compound) resembles Drospirenone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone (Compound) resembles Drospirenone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Drospirenone (Compound)